Neuraxpharm reports another year of sustained growth and international expansion
CNS specialist continues growth strategy across Europe and beyond, optimizing commercial efficiency and maintaining strong focus on innovation
Barcelona, Spain and Düsseldorf, Germany – 14 November 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its rebranding as Neuraxpharm and its repositioning as a leading European CNS-focused pharma.
